47 research outputs found
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding to use endocrine therapy for breast cancer risk reduction.; An Expert Panel conducted targeted systematic literature reviews to identify new studies.; A randomized clinical trial that evaluated the use of anastrozole for reduction of estrogen receptor-positive breast cancers in postmenopausal women at increased risk of developing breast cancer provided the predominant basis for the update.; In postmenopausal women at increased risk, the choice of endocrine therapy now includes anastrozole (1 mg/day) in addition to exemestane (25 mg/day), raloxifene (60 mg/day), or tamoxifen (20 mg/day). The decision regarding choice of endocrine therapy should take into consideration age, baseline comorbidities, and adverse effect profiles. Clinicians should not prescribe anastrozole, exemestane, or raloxifene for breast cancer risk reduction to premenopausal women. Tamoxifen 20 mg/day for 5 years is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. Data on low-dose tamoxifen as an alternative to the standard dose for both pre- and postmenopausal women with intraepithelial neoplasia are discussed in the Clinical Considerations section of this article. Additional information is available at www.asco.org/breast-cancer-guidelines
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
Panel Discussion
More than 300 public health officials, medical researchers, and patient advocates Data from the central Appalachian Region show disparities in excess morbidity and mortality in cancers of the lung and colon, and historical disparities in cervical cancer incidence and mortality. Contributing to the cancer burden are limited access to quality care, lack of insurance, lack of education. and limited literacy skills. There are, however, characteristics of the people of this region that have contributed to the successful implementation of community initiated interventions. The Community Cancer Education Program is a grassroots initiative designed to encourage and empower community organizations to implement effective cancer education projects. This Program allows health issues identified as important at the local level to be addressed with audiences not otherwise reached. This presentation will describe the region and the factors that led to enhanced cancer control capacity
Factors influencing recurrence in long-term survivors with early-stage breast cancer of low risk.
Demographic, clinical and geographical factors associated with lack of receipt of recommended chemotherapy.
Current Knowledge on Contralateral Prophylactic Mastectomy Among Women with Sporadic Breast Cancer
This review evaluates current data on the clinical indications for CPM and long-term patient satisfaction and psychosocial outcomes
Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors.
Physical activity (PA) is a known behavior to reduce cancer risk and improve cancer survivorship, yet adherence to PA guidelines is poor among the general population and cancer survivors. The purpose of this study was to determine the extent to which patients referred for exercise consultation within a clinical cancer prevention setting were meeting aerobic and resistance physical activity (PA) guidelines and to identify factors associated with guideline adherence. Between 2013 and 2015, cancer prevention patients and cancer survivors were interviewed by an exercise physiologist within an Integrative Health Program at The University of Texas MD Anderson Cancer Prevention Center. PA adherence was defined as at least 150-minutes of moderate-intensity or 75-minutes of vigorous-intensity PA per week, along with resistance training at least 2 days per week. Logistic regression was used to determine factors associated with meeting or not meeting PA guidelines for aerobic exercise, resistance exercise, and aerobic and resistance exercise combined. Among 1,024 cancer prevention patients and survivors, 9% of patients adhered to guideline-based PA. Adherence to aerobic and resistance guidelines were 20% and 12%, respectively. Overweight or obesity was associated with not meeting guideline-based PA in both cancer prevention patients and cancer survivors. Among breast cancer survivors, combination treatment with surgery, radiation, and chemotherapy ('multimodal therapy') was robustly associated with not meeting aerobic guidelines (OR 2.20, 95% CI: 1.17 to 4.16). BMI and breast cancer treatment history are key determinants of PA behavior among cancer prevention patients and survivors. Poor adherence to PA guidelines is a key issue for cancer prevention patients and survivors, particularly obese patients and women who receive multimodal therapy for breast cancer. Identifying and connecting patients at highest risk of poor PA adherence with exercise programs is needed to improve PA, a key modifiable cancer risk factor